Teva Pharmaceutical and the US Federal Trade Commission have reached a settlement to end their long-running battles over so called “pay-for-delay” agreements in the pharmaceutical industry.
The US Food and Drug Administration has published new draft guidance on a pathway intended to boost the development of generics and lower drug prices.
While the final text of the European Council’s agreement on a supplementary protection certificate manufacturing waiver has yet to be released, the reported stockpiling provision has attracted criticism.
The Court of Justice of the European Union has issued a judgment in favour of Warner-Lambert amid a dispute between the American pharmaceutical company and an administrative body in the Netherlands.
Johnson & Johnson has announced plans to strengthen its robotics programme with the addition of Silicon Valley-based Auris Health to its business.
The European Council has reached a political agreement on a proposal for the supplementary protection certificate manufacturing waiver for patent-protected pharmaceuticals.
Bayer suffered defeat at the hands of the EU General Court today, with the rejection of its attempt to register what the court deemed to be heart-related trademark.
Israel-based Teva has predicted 2019 will be a tough year, with lower revenue and profit, as the company faces generic competition for two of its top-selling drugs.
The EU General Court has dismissed an appeal from German company Nemius Group against a decision to refuse registration for its ‘Dentaldisk’ mark.
The Canadian units of IBM and pharmaceutical company Boehringer Ingelheim have united to explore the use of blockchain technology in clinical trials.